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A B S T R A C T
Integrin αvβ6 is a membrane-spanning heterodimeric glycoprotein involved in wound healing and the patho-
genesis of diseases including fibrosis and cancer. Therefore, it is of great clinical interest for us to understand the
molecular mechanisms of its biology. As the limiting binding partner in the heterodimer, the β6 subunit controls
αvβ6 expression and availability. Here we describe our understanding of the ITGB6 gene encoding the β6
subunit, including its structure, transcriptional and post-transcriptional regulation, the biological effects ob-
served in ITGB6 deficient mice and clinical cases of ITGB6 mutations.
Introduction
Integrins are heterodimeric cell surface proteins that facilitate sig-
nalling between the intracellular and extracellular environments. Each
integrin consists of one α and one β subunit. Together, they are capable
of forming 24 unique integrins in humans (reviewed by Hynes, 2002).
αvβ6 is expressed exclusively on epithelial cells but is absent or ex-
pressed at low levels in normal healthy adult tissue (Breuss et al.,
1993). In contrast, αvβ6 expression is increased during development
(Breuss et al., 1995), wound healing (Haapasalmi et al., 1996), cancer
(reviewed by Bandyopadhyay and Raghavan, 2009) and fibrosis
(Munger et al., 1999), all of which are processes requiring tissue re-
modelling (Fig. 1).
αvβ6 binds to proteins containing the RGD (Arg-Gly-Asp) motif
(Busk et al., 1992). Well characterised αvβ6 ligands include fibronectin
(Busk et al., 1992) and the Transforming Growth Factor Beta (TGF-β)
pro-peptide, Latency Associated Peptide (LAP) (Munger et al., 1999;
Annes et al., 2002). LAP is post-translationally cleaved from TGF-β1 but
remains directly associated with the cytokine, anchored as a homo-
dimer to the extracellular matrix (ECM) via latent TGFβ binding protein
1 (Annes et al., 2004). This whole complex remains inert and is referred
to as latent TGF-β1. Binding of αvβ6 to LAP physically moves LAP and
exposes TGF-β1 to its receptors on adjacent cells, permitting an acto-
myosin dependent activation of TGF-β1 (Munger et al., 1999, Annes
et al., 2004). Binding domains are also present on the cytoplasmic tail
of integrin β6, which recruits signalling and structural partners
including HAX-1, Fyn, ERK2, and Kindlin-1 (Ahmed et al., 2002; Li
et al., 2003; Ramsay et al., 2007; Moser et al., 2008). Extracellular li-
gand binding to αvβ6 is able to effect a conformational change in the
cytoplasmic tail and thus initiate downstream signalling (outside-in
signalling), while cytoplasmic tail binding may also affect extracellular
ligand binding (inside-out signalling).
Through these and other signalling pathways, αvβ6 regulates many
basic functions of the cell, such as proliferation (Agrez et al., 1994),
migration (Huang et al., 1998), and ECM degradation (Thomas et al.,
2001; Morgan et al., 2004). Expression of αvβ6 is found in up to one
third of all solid tumours (Saha et al., 2010) and is associated with a
poorer prognosis and increased invasiveness (Niu and Li, 2017). αvβ6
expression is also associated with the progression of pulmonary fibrosis
through its activation of TGF-β1 (Goodwin and Jenkins, 2009).
The β6 subunit was first isolated from guinea pig epithelial cells in
1990 (Sheppard et al., 1990). At this time, only three β subunit struc-
tures had been identified in mammalian cells, with emerging evidence
for several other subunits (Cheresh et al., 1989). Sheppard and collea-
gues, observing that β1, β2 and β3 had large consensus regions in their
sequences, designed primers against these conserved regions and suc-
cessfully amplified β6. Further screening in human cell lines led to the
identification of the β6 nucleotide sequence from the pancreatic cell
line FG-2. It was later determined that ITGB6 was located on chromo-
some 2 (Krissansen et al., 1992), specifically 2q24.2 (Fernandez-Ruiz
and Sanchez-Madrid, 1994).
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Transcriptional regulation
As the exclusive binding partner of αv, β6 availability determines
the cellular expression of αvβ6. Breakthrough work characterising the
structure and transcriptional regulation of ITGB6 was performed by Xu
et al., 2015. They identified both the transcriptional start site (TSS),
204 bp upstream of the translation initiation site, and the core promoter
of ITGB6 using oral squamous cell carcinoma cells (OSCCs). A func-
tional TATA box was located -24bp to -18bp upstream of the TSS, and
binding sites for transcription factors C/EBPα (CCAAT-enhancer-
binding protein α) and signal transducer and activator transcription 3
(STAT3) between -289bp and -150bp. Further binding sequences for
Ets-1 and Smad proteins were also identified, however the basal rate of
ITGB6 expression in OSCC cells was primarily defined by STAT3 and C/
EBPα binding (Xu et al., 2015).
This was not the first time STAT3 had been implicated in the pos-
sible regulation of ITGB6. Previous work showed that constitutive
STAT3 activation led to an increase in cell migration and motility in
prostate cancer cell lines (Azare et al., 2007). This was attributed to an
increase in ITGB6 mRNA expression within 4 hours of STAT3 simula-
tion, whereas inhibition of STAT3 by shRNA resulted in downregulation
of ITGB6 mRNA.
Work performed in colon carcinoma cell lines by Bates and collea-
gues in 2005 also revealed a binding domain for Ets-1 in the ITGB6
promoter region. As an initiating factor of the epithelial-mesenchymal
transition (EMT), it was hypothesised that Ets-1 could possibly play a
role in ITGB6 expression. They demonstrated that Ets-1 was able to bind
to the ITGB6 promoter region and transactivate the promoter, resulting
in increased ITGB6 transcription (Bates et al., 2005).
In 1992, it was discovered that TGF-β1 works as part of a positive
feedback loop promoting expression of αvβ6 (Sheppard et al., 1992). In
an effort to determine the mechanisms by which TGF-β1 regulates
ITGB6 expression using a pulmonary fibrosis model, Tatler and col-
leagues identified the location of a suppressor region in the ITGB6 gene
(Tatler et al., 2016a,b). They found that deletion of the region -818bp to
-738bp leads to a significant increase in ITGB6 expression. This
confirmed work by Xu and colleagues, who also showed that deletion
from -909bp to -421bp leads to maximum transcriptional activity (Xu
et al., 2015).
Another transcription factor of the Ets family was also shown to
have a role in regulating ITGB6 (Tatler et al., 2016a,b). Following in
silico analysis, it was found that the ETS domain-containing protein
Elk1 was able to bind to a site in the apparent suppressor region and
reduce ITGB6 expression. Loss of Elk1 in vivo led to an increased basal
expression ITGB6 mRNA (Tatler et al., 2016a,b).
Smad transcription factors mediate classical TGF-β1 signalling
(Derynck et al., 1998). Disruption of a Smad binding site within the
same suppressor region of ITGB6 (-818bp to -738bp) led to abrogation
of ITGB6 transcription induced by TGF-β1 (Tatler et al., 2016a,b). In-
hibition of Smad3 led to a decrease in ITGB6 transcription and, more-
over, Smad3-/- mice treated with TGF-β1 had reduced expression of
αvβ6. TGF-β1-induced ITGB6 expression regulated by Smad proteins
has been extensively documented, including in bile duct epithelial cells
(BDECs) where Smad3 inhibition reduced TGF-β1 induced ITGB6
mRNA (Verrecchia and Mauviel, 2002; Schiffer et al., 2000). Con-
versely, Xu and colleagues (2015) concluded that Smad binding domain
activity was not essential for basal expression in OSCCs.
Regulation of ITGB6 by TGF-β1 was further explored by Xu and
colleagues (2017). They identified that the AP1 subunit JunB binds
directly to the ITBG6 promoter region. Furthermore, they identified a
role for histone H3 and H4 acetylation following treatment with TGF-β.
Inhibition of Histone Deacetylase (HDAC) resulted in increased acet-
ylation of H3 and H4, leading to an increased expression of ITGB6.
Histone acetylation was initiated by recruitment of the cAMP response
element binding protein (CBP), which acts as both a histone acetyl-
transferase (HAT) and a scaffold that promotes the recruitment of fur-
ther components required for gene transcription (Korzus et al., 2004).
Given that transcription of ITGB6 is almost certainly a mechanism
determining its availability at the cell surface, understanding its reg-
ulation could identify potential therapeutic targets in diseases where
αvβ6 is overexpressed. Although recent work has greatly improved our
understanding of the structure of the promoter region, and binding sites
Fig. 1. ITGB6 RNA expression in human normal tissue plotted as rates per kilobase million (RPKM). Data were obtained from Human Protein Atlas Dataset available
from proteinatlas.org.
< https://www.proteinatlas.org/ENSG00000115221-ITGB6/tissue#gene_information >
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of transcription factors, extensive work still remains to fully char-
acterise how these transcription factors regulate ITGB6 transcription
(Fig. 2).
Post-Transcriptional Regulation
Following gene transcription, protein expression may also be regu-
lated by multiple post-transcriptional processes. One of the most sig-
nificant points of post-transcriptional regulation happens at the initia-
tion of mRNA translation. Eukaryotic translation initiation factor 4
(eIF4E) binds to the 5’ end of mRNA, initiating protein translation
(Rhoads, 1988). eIF4E is known to selectively increase the expression of
proteins with ‘weak’ mRNA (Graff and Zimmer, 2003). This refers to
proteins with a long and/or complex 5’ UTR (untranslated region),
usually proteins expressed at low levels in healthy tissue, as opposed to
‘strong’ mRNAs, which have a short and simple 5’UTR and are usually
housekeeping genes. eIF4E expression is known to be dysregulated in
malignancy (, Siddiqui and Sonenberg, 2015). De Benedetti and Graff
(2004) reviewed the effect of eIF4E in malignancy, describing its ability
to selectively upregulate translation of some pro-tumorigenic proteins
(e.g. Vascular Endothelial Growth Factor (VEGF)), which tend to have a
more complex 5’UTR and require eIF4E for translation.
ITGB6 mRNA has a long 5’-UTR and is GC rich, both of which are
characteristics of ‘weak’ mRNA. Combined expression of eIF4E and
ITGB6 can predict a poorer prognosis in colon cancer (Niu et al., 2014).
Furthermore, siRNA-induced depletion of eIF4E significantly reduced
protein expression of β6 (Enyu et al., 2015). Further investigation in to
eIF4E and αvβ6 expression in other models has yet to be performed.
Thus, while we now know a significant number of the transcriptional
regulators of ITGB6, we have not yet linked these data to how ITGB6 is
upregulated in disease, especially cancer.
Mouse Models
Itgb6 knockout mice have been used to study the downstream effects
of αvβ6 and improve our understanding of its biology. The first char-
acterisation of Itgb6 deficient mice was published in 1996, with sur-
prising results (Huang et al., 1996). Given the role αvβ6 plays in wound
healing in human tissue (Haapasalmi et al., 1996), it was hypothesised
that Itgb6 knockout mice would exhibit wound healing abnormalities.
The authors also postulated that Itgb6 knockout mice would display
developmental abnormalities due to the involvement of αvβ6 in cell
migration and proliferation (Agrez et al., 1994; Huang et al., 1998).
However, the Itgb6 knockout mice developed normally, with no dif-
ference in their wound healing ability. Rather, they exhibited moderate
but significant inflammation in the lungs and skin. In the same study,
Itgb6 knockout mice did not develop fibrosis in response to bleomycin.
This phenotype is remarkably similar to TGF-β1 deficient mice, and is
attributable to TGF-β1 activation by αvβ6 (Munger et al., 1999). In-
terestingly, inflammation was only observed in the skin and airways of
Itgb6 knockout mice, despite the potential for expression of αvβ6 in
other epithelial tissues. The authors offered this was perhaps due to the
housing conditions of the mice causing irritation in the skin and lungs.
Neonatal Itgb6 knockout mice also developed a temporary baldness.
Whether this was due to the subsequent discovery that αvβ6 plays a
role in hair follicle regeneration remains to be determined (Xie et al.,
2012).
The fibrosis phenotype of Itgb6 knockout mice was further explored
in Itgb6/Thrombospondin 1 (Tsp-1) double-null mice (Ludlow et al.,
2005). Thrombospondin-1 also activates latent-TGF-β1 (Crawford et al.,
1998) and in the double knockout model there was a higher incidence
of inflammation and pneumonia, which more closely resembles the
phenotype of TGF-β1 null mice (Shull et al., 1992). Whilst no sig-
nificant differences in tumour incidence were observed between the
Itgb6-/- and the Itgb6-/; Tsp-1-/- mice, the authors found that Itgb6-/- mice
developed both benign and malignant tumours at a significantly higher
rate than the Tsp-/- mice.
Another characteristic of Itgb6-/- mice is their eventual development
of emphysema (Morris et al., 2003). In the alveolar macrophages of
Itgb6-/- mice, MMP12, an enzyme strongly associated with the patho-
genesis of emphysema, is expressed 200-fold higher than in wild-type
counterparts (Houghton, 2015). Although at birth the size of the alveoli
is normal, by six months of age the alveolae of Itgb6-/- mice are sig-
nificantly larger and exhibit mild emphysema, which increases in se-
verity with age (Houghton, 2015).
Mice deficient in Itgb6 develop chronic periodontal disease (peri-
odontitis) (Ghannad et al., 2008), an advanced stage of gingivitis in
which the gums pull away from the teeth, leaving space or ‘pockets’
between the teeth and gums that become infected. The consequent
immune response leads to degradation of the connective tissue between
the teeth and gums. An important interface in the development of
periodontal disease is the junctional epithelium (JE), which expresses
αvβ6 and is involved in adhesion of the gingiva to the teeth. By 12
months of age, Itgb6-/- mice develop abnormal JE, exhibit periodontal
pockets and show evidence of inflammation and bone degradation
(Ghannad et al., 2006; Bi et al., 2017).
Itgb6-/- mice also develop amelogenesis imperfecta, a disorder af-
fecting the development of teeth (Mohazab et al., 2013). Amelogenesis
imperfecta causes a range of symptoms, including abnormally small
teeth prone to breakage and discolouration. Cases of amelogenesis
imperfecta have also been observed in clinical studies in patients with
ITGB6 mutations (Wang et al., 2014; Poulter et al., 2014).
Clinical Cases of ITGB6 mutations
The first clinical case associated with an ITGB6 mutation was
documented in 2013, in which a 7-year-old girl presented with enamel
malformations but was otherwise asymptomatic (Wang et al., 2014).
Following whole genome sequencing, it was revealed that she had in-
herited 2 distinct missense mutations in ITGB6. As part of the same
study, a second child displaying symptoms of amelogenesis imperfecta
was examined and he too had a bi-allelic ITGB6 mutation. Poly-
morphism Phenotyping (Polyphen) analysis indicated that both muta-
tions were of high probability of affecting β6 protein structure and
causing disease. These and other cases of ITGB6 mutations have been
documented across a number of conditions (Table 1).
These cases were the first reported examples of mutations in the
ITGB6 gene causing amelogenesis imperfecta. Interestingly, they re-
ported no other clinical symptoms, such as pulmonary inflammation as
reported in mouse models. However, it is unknown whether the authors
performed a detailed clinical examination of the children. Similarly,
further reported cases of amelogenesis imperfecta with ITGB6 muta-
tions failed to disclose other possible clinical symptoms, or whether
these were investigated (Poulter et al., 2014).
There is a collection of clinical cases where a large deletion in the
2q24 region encompassing the ITGB6 gene has resulted in respiratory
complications in the patient (Takatsuki et al., 2010). These authors
described a case of a 2-month-old girl who, among other symptoms,
Fig. 2. ITGB6 Gene Promoter Region Structure. ITGB6 contains a TATA box -18
bp upstream of the TSS (Transcriptional Start Site). An area found to promote
ITGB6 transcription is located at -289bp to 150 bp, including binding domains
for C/EBPα (CCAAT-enhancer-binding protein α), AP-1 (Activator Protein 1)
and STAT3 (Signal transducer and activator of transcription 3). A suppressor
region can be found -738bp to -818bp with a binding region for Elk1 ETS Like-1
protein). Smad3 (Smad Family Member 3) binding domain is also found in this
region, but results in ITGB6 promotion. Translation Initiation Site (TIS) is found
+204 bp downstream of the TSS. (Xu et al., 2015; Tatler et al., 2016a,b.
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developed severe pulmonary emphysema. After confirming ITGB6 was
deleted, they hypothesised that there was a relationship between this
deletion and the respiratory complications experienced by the child.
However, it is estimated that a total of 34 genes were affected by this
deletion. Thus, her emphysema may not have been caused by the ITGB6
deletion alone, despite the similarities in phenotype with the Itgb6-/-
mice. A further three cases (Shabtai et al., 1982; Moller et al., 1984 and
Langer et al., 2006) document patients with large deletions in the 2q24
region that included ITGB6, two of which resulted in fatalities caused
by respiratory complications.
A novel homozygous missense mutation in ITGB6 was found in three
members of a Pakistani family presenting with alopecia, intellectual
disabilities, and symptoms consistent with amelogenesis imperfecta
(Ansar et al., 2016). It is perhaps worth noting that cognitive dis-
abilities have not been noted in experimental mouse studies of Itgb6.
The mutation was found in a highly conserved region of ITGB6 which
was predicted by in silico analysis to cause significant change to β6,
which may its function. Thus, humans with loss of function ITGB6
mutations exhibit some of the phenotypes observed in Itgb6-/- mice
(alopecia, amelogenesis imperfecta, periodontitis, and emphysema) but
this seems to vary between individuals, presumably due to the clinical
severity of the different mutations. Further clinical exploration will
result in a clearer picture of how specific mutations manifest.
Conclusions
Although a substantial amount of work has been performed to de-
termine the structure of the ITGB6 gene, there are many unanswered
questions as to how β6 protein expression is regulated. Of note, limited
work has been performed to further our understanding of post-tran-
scriptional regulation of ITGB6, which likely plays a significant role in
αvβ6 expression and biology. Furthermore, investigations of clinical
cases involving ITGB6 mutations have not been comprehensive and it is
possible we have missed some understanding of the human phenotype
that would help us fully appreciate the role of ITGB6 in humans.
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